Cencora — Nov 6, 2024 release

Please refer to the Supplemental Information Regarding Non-GAAP Financial Measures following the tables for additional information. Fiscal Year 2025 Expectations on an Adjusted (non-GAAP) Basis Cencora has introduced its full fiscal year 2025 financial guidance, which reflects adjusted operating income growth of 5 percent to 6.5 percent and adjusted diluted EPS growth of 8 percent to 10 percent. Since the Company’s preliminary fiscal 2025 guidance provided on its Form 8-K filed on September 5, 2024, Cencora has executed on opportunistic share repurchases in September and October and had continued momentum in the business. The Company expects: • Revenue growth to be in the range of 7 to 9 percent; ◦ U.S. Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent; ◦ International Healthcare Solutions segment revenue growth to be in the range of 7 to 9 percent; • Adjusted diluted earnings per share to be in the range of $14.80 to $15.10.     Additional expectations include: • Adjusted operating income growth to be in the range of 5 to 6.5 percent; ◦ U.S. Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent; ◦ International Healthcare Solutions segment operating income growth to be in the range of 5 to 6.5 percent; • Interest expense to be in the range of $150 million to $170 million; • Adjusted effective tax rate of approximately 21 percent; • Adjusted free cash flow to be in the range of $2.0 billion to $3.0 billion; • Capital expenditures to be approxima